Outcome of thalassemia treated with conventional therapy.
Borgna-Pignatti
C
C
Zurlo
M G
MG
DeStefano
P
P
Boffa
C
C
DeSanctis
V
V
DiPalma
A
A
DiGregorio
L
L
Melevendi
C
C
Piga
A
A
Sabato
V
V
D000293:Adolescent; D001803:Blood Transfusion; D002318:Cardiovascular Diseases / Q000209:etiology / Q000401:mortality; D002423:Cause of Death; D015913:Chelation Therapy; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D003676:Deferoxamine / Q000627:therapeutic use; D004700:Endocrine System Diseases / Q000209:etiology / Q000401:mortality; D005260:Female; D006130:Growth Disorders / Q000209:etiology; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007501:Iron; D007558:Italy / Q000453:epidemiology; D015993:Life Tables; D008107:Liver Diseases / Q000209:etiology / Q000401:mortality; D008297:Male; D011628:Puberty, Delayed / Q000209:etiology; D013156:Splenectomy; D016019:Survival Analysis; D016896:Treatment Outcome; D017086:beta-Thalassemia / Q000150:complications / Q000401:mortality / Q000628:therapy*
D007501:Iron; D003676:Deferoxamine